To identify chromosomal regions that may contain loci for tumor suppressor genes involved in adrenocortical tumor development, a panel of 60 tumors (39 carcinomas and 21 adenomas) were screened for loss of heterozygosity. Although the vast majority of loss of heterozygosity (LOH) were detected in the carcinomas and involved chromosomes 2, 4, 11, and 18, only few were found in the adenomas. Therefore, 2 loci that harbor the familial cancer syndromes Carney complex in 2p16 and the multiple endocrine neoplasia type 1 gene in 11q13 were further studied in 27 (13 carcinomas and 14 adenomas) of the 60 tumors. Detailed analysis of the 2p16 region mapped a minimal area of overlapping deletions to a 1-centimorgan region, which is separate from the Carney complex locus. LOH for a microsatellite marker (PYGM), very close to the MEN1 gene, was detected in all 8 informative carcinomas (100%) and in 2 of 14 adenomas. Of the 27 cases analyzed in detail, 13 cases (11 carcinomas and 2 adenomas) showed LOH on chromosome 11 and was therefore selected for MEN1 gene mutation analysis. In 6 cases a common polymorphism (Asp 418 Asp) was found, but no mutation was detected. In conclusion, our data indicate the existence of tumor suppressor genes at multiple chromosomal locations, whose inactivations are involved in the development of adrenocortical carcinomas. Loss of genetic material from 2p16 was strongly associated with the malignant phenotype, as it was seen in almost all carcinomas but not in any of the adenomas. LOH in 11q13 also occurred frequently in the carcinomas, but was not associated with a MEN1 mutation, suggesting the involvement of a different tumor suppressor gene on this chromosome. (J Clin Endocrinol Metab 84: 730 -735, 1999) 
in all 8 informative carcinomas (100%) and in 2 of 14 adenomas. Of the 27 cases analyzed in detail, 13 cases (11 carcinomas and 2 adenomas) showed LOH on chromosome 11 and was therefore selected for MEN1 gene mutation analysis. In 6 cases a common polymorphism (Asp 418 Asp) was found, but no mutation was detected. In conclusion, our data indicate the existence of tumor suppressor genes at multiple chromosomal locations, whose inactivations are involved in the development of adrenocortical carcinomas. Loss of genetic material from 2p16 was strongly associated with the malignant phenotype, as it was seen in almost all carcinomas but not in any of the adenomas. LOH in 11q13 also occurred frequently in the carcinomas, but was not associated with a MEN1 mutation, suggesting the involvement of a different tumor suppressor gene on this chromosome. (J Clin Endocrinol Metab 84: 730 -735, 1999) A DRENOCORTICAL lesions most often occur sporadically, but are also found in conjunction with familial tumor syndromes such as Beckwith-Wiedemann (11p15.5), Li-Fraumeni (TP53 in 17p13), multiple endocrine neoplasia type 1 (MEN1), and Carney complex (CC). MEN1 is an autosomal dominant disease characterized by neoplasia of the parathyroid glands, the endocrine pancreas, and the anterior pituitary gland. In addition, the patients may develop adrenocortical tumors, carcinoids, thyroid nodules, and lipomas (1) . The involvement of the adrenal gland has been reported in about 40% of MEN1 patients and represent bilateral hyperplasia, adenomas and in a few cases carcinomas (2) (3) (4) . The MEN1 tumor suppressor gene in 11q13 (5) was recently cloned (6, 7) and has since been shown to be somatically mutated in half of the sporadic parathyroid, pancreatic, and pituitary tumors displaying a concomitant loss of one 11q13 allele (1) . The CC is a familial multiple neoplasia syndrome inherited in an autosomal dominant manner. Affected family members may develop primary pigmented nodular adrenocortical disease, lentiginosis, myxomas, and a variety of endocrine and nonendocrine tumors. The CC locus has been assigned to 2p16, but the gene has not yet been cloned (8) .
Studies of genetic alterations in adrenocortical tumors have demonstrated the involvement of multiple chromosomal regions, which to some extent overlap with the mapping of the familial forms of these tumors. Thus, both familial and sporadic adrenocortical tumors show loss of heterozygosity/allelic imbalance (LOH/AI) for markers in 11p, 11q, and 17p. Comparative genomic hybridization performed on 22 sporadic tumors showed an increased number of sequence copy number aberrations by tumor size in carcinomas, whereas the benign tumors were genetically more stable (9) . Moreover, losses were most often found on chromosomes 2, 11, and 17, whereas gains were detected on chromosomes 4 and 5. The results suggest that putative tumor suppressor genes (TSG) and oncogenes are located on these chromosomes. Other studies have focused on genetic alterations within candidate genes such as TP53, p21, ACTH receptor, CYP-21, and IGF2 (10 -16a).
Here we have applied LOH analysis to a panel of adrenocortical adenomas and carcinomas to identify chromosomal regions that may be involved in the development and progression of this tumor form. With the aim to get an insight into the importance of the MEN1 gene and CC locus, the 11q13 and 2p16 regions were analyzed in more detail. Furthermore, mutation analysis of the MEN1 gene was performed.
Subjects and Methods

Patients and tumor samples
This study includes matched pairs of constitutional and tumor samples from 60 patients with primary sporadic adrenocortical tumors (39 carcinomas and 21 adenomas) operated on between 1973 and 1995. The tumors were classified as malignant or benign based on histopathological findings (invasion, necrosis, pleomorphism, and number of mitosis), tumor size (median, 7.5; range, 0.5-22.0 cm), and clinical outcome. Endocrine symptoms were present in 38 of the patients; 17 showed signs of Cushing's disease (11 carcinomas and 6 adenomas), 4 showed virilization (carcinomas), 2 showed feminization (carcinomas), and 15 were classified as having Conn's disease (4 carcinomas and 11 adenomas). Fifty-six of the tumors were screened for LOH/AI on chromosome 1 to X (the Y chromosome was not analyzed). Four additional carcinomas from patients 2, 6, 11, and 12 were included after the initial screening had been performed and were only analyzed for LOH/AI on chromosomes 2, 4, 11, 14, 17, 18, and 22 ( Table 2 ). Further analysis of 11q13 and 2p16 was performed in 27 tumors (13 carcinomas and 14 adenomas) for which normal and tumor tissue was still available. The MEN1 gene was subsequently screened for mutations, using single strand conformation analysis (SSCA), in the 11 carcinomas and in the 2 adenomas that showed chromosome 11 LOH/AI. Informed consent was obtained from all living patients, and the study was approved by the ethical committee of the Karolinska Hospital.
DNA isolation
Immediately after surgical removal, adrenocortical tissue was frozen in liquid nitrogen and stored at Ϫ70 C. High mol wt DNA was extracted from 27 frozen tumor tissues by phenol chloroform extraction and ethanol precipitation according to standard methods. To ensure representativity of the tumor material, pieces were cut from all specimens for histopathological examination, and the samples that were included in the study contained 70% or more tumor cells. In 33 cases where no frozen tumor tissue was available, tumor DNA was obtained from sections of routinely processed paraffin-embedded tumor tissue as previously described (17) . In short, 5-m sections were deparaffinized with lemonene, and tumor cell areas were dissected and incubated with proteinase K in lysis buffer [500 g/mL proteinase K, 0.05 m Tris-HCl (pH 7.9), 0.15 m NaCl, 5 mm ethylenediamine tetraacetate, and 1% SDS] at 45 C overnight, followed by phenol-chloroform extraction and ethanol precipitation. Constitutional DNA was extracted from peripheral leukocytes or paraffin-embedded normal tissues.
LOH/AI studies
The 36 microsatellite markers used for the initial screening and their chromsomal localizations are detailed in Table 1 . Standard PCR reactions were carried out on microtiter plates in a final volume of 50 L containing 40 ng constitutional or tumor DNA, 10 mm Tris base (pH 9), 50 mm KCl, 1.5 mm MgCl 2 , 0.1% (vol/vol) Triton X-100, 0.01% (wt/vol) gelatin, 50 pmol of each primer, 1.25 mm of each deoxy (d)-NTP, and 1 U Taq polymerase. Samples were amplified using a hot start, with Taq polymerase added after a 5-min denaturation step at 96 C, followed by 35 two-step cycles with annealing at 55 C for 30 s and denaturation at 94 C for 40 s, and a final elongation step at 72 C for 2 min. To minimize the number of sequencing gels and gel loadings, a procedure developed by Hazan et al. (18) was used. In short, PCR amplifications of different markers from the same genomic DNA sample were pooled and loaded into a single well of a sequencing gel. After migration, the products were transferred onto a nylon filter (Hybond N ϩ ) and hybridized with one of the primers (end labeled with 33 P) used in the PCR reaction. The filters were then subjected to autoradiography for 7-10 days.
The following microsatellite markers were used for the additional studies of LOH/AI on chromosomes 2 and 11: D2S319, POMC, D2S391, D2S288, CA5, CA7, D2S123, CA2, and D2S125 on chromosome 2 and D11S909, PYGM, D11S449, and D11S968 on chromosome 11. PCR analyses were performed using standard methods. One primer was end labeled with 32 P. The thermal cycling conditions were incubation at 94 C for 4 min, followed by 30 step cycles of 94 C for 1 min, 60 C for 1 min, and 72 C for 1 min, and a final extension for 7 min at 72 C. Aliquots of the PCR product were electrophoresed in denaturing 6% polyacrylamide DNA sequencing gels. Gels were then subjected to autoradiography for 12-24 h.
The location and order of markers are according to GDB (http:// www.gdb.org). LOH/AI was defined as either a total absence or a reduction by 50% or more of the signal intensity of one of the constitutional alleles in the tumor compared to the constitutional DNA that could be detected visually.
SSCA
The nine coding exons of the MEN1 gene were amplified using 15 different fragments of 200 -300 bp each, as previously described (7). Fifty nanograms of genomic DNA were amplified by PCR in 50 mm KCl; 10 mm Tris-HCl (pH 9.0); 1.5 mm MgCl 2 (Promega Corp., Madison, WI); 0.2 mm dTTP, dCTP, and dGTP; 0.05 mm dATP; and [␣-
32 P]dATP (Amersham, Arlington Heights, IL) at 1 mCi/reaction and 2 U Taq DNA polymerase (Promega Corp.) in a final volume of 15 L. Thermocycling conditions were 30 cycles of 1 min at 94 C, 1 min at 62 C, followed by one cycle of 5-min extension at 72 C. The PCR products were then electrophoresed in 25% MDE (FMC, Rockland, ME) gels at room temperature for 12 h at 6 -8 watts. Gels were dried before autoradiography.
Direct DNA sequencing
SSCA-shifted bands were excised from the MDE gel and placed in 50 L ddH 2 O at 37 C for 1 h. A 5-L aliquot of this solution was then amplified in a 50-L reaction with the following components: 50 mm KCl; 10 mm Tris-HCl (pH 9.0); 1.5 mm MgCl 2 (Promega Corp.); 0.2 mm dTTP, dCTP, dGTP, and dATP; and 15 U Taq DNA polymerase (Promega Corp.). The purified PCR products were sequenced using cycle sequencing reactions from the ABI PRISM 377 BigDye Primer cycle sequencing kit (Perkin-Elmer, Norwalk, CT) and run on the automated sequencer ABI 377 (PE Applied Biosystems, Foster City, CA).
Results
Genotyping of adrenocortical tumors
In the present study adrenocortical carcinomas and adenomas from 60 patients were screened for LOH/AI using microsatellite markers (Table 1) . For the acrocentric chromosomes, one locus on the q-arm was analyzed, and for most of the nonacrocentric chromosomes, markers on both the pand q-arms were tested. As several of the DNA samples were isolated from paraffin-embedded tissues, all samples did not amplify for all the markers. Overall LOH/AI was detected on most chromosomes, and in frequencies that varied between 0 -29%. Detailed study of the LOH/AI with regard to the malignant (39 cases) and benign (21 cases) classification revealed that the vast majority of losses occurred in the carcinomas. In the carcinomas the LOH/AI frequency per marker varied from 0 -60%, and in the adenomas it varied from 0 -14%. Similarly, the individual variation in the number of detectable chromosomal alterations fell within a range of 0 -18 for the carcinomas and 0 -2 for the adenomas.
Allele losses were detected in 79 of 813 informative instances (Table 1) . Seventy-four of these occurred in the carcinomas, and most often involved chromosome arms 2q (50%), 4p (44%), 11p (60%), 11q (47%), and 18p (57%; Table  1 and Fig. 1). In addition, 1p, 1q, 3p, 6q, 8p, 14q, 17p, 17q, 18q , 22q, and Xp showed LOH/AI in 20 -36% of the informative cases. The five losses identified in the adenomas involved five different chromosome arms, i.e. 1q, 3q, 4q, 14q, and 18q (Table 1) . Among the carcinomas, the larger tumors showed an increased number of LOH/AI compared to the smaller tumors. However, the pattern of chromosomes involved did not differ between tumors of different hormonal status.
Twenty-seven tumors (13 carcinomas and 14 adenomas) were further analyzed for LOH/AI within chromosomal regions 11q13 and 2p16, where the MEN1 gene and CC locus are located, respectively. Furthermore, mutation screening of the MEN1 gene was performed in 13 of these cases (11 carcinomas and 2 adenomas). Table 2 shows the clinical, morphological, hormonal, and genetic data for each patient in this subgroup.
LOH/AI in chromosome 11q13 and mutation analysis of the MEN1 gene
The PYGM marker located very close to the MEN1 gene in 11q13 showed LOH/AI in all 8 informative carcinomas (100%) and in 2 of the 13 informative adenomas (13%). How- ever, losses were less frequent in the distal parts of chromosome 11. One of the carcinomas and the 2 adenomas with loss of PYGM (cases 4, 21, and 27) showed retained heterozygosity with D11S909 in 11pter (Fig. 2) . Similarly, no losses were detected with D11S968 at 11qter in 3 carcinomas and 1 adenoma displaying LOH for PYGM in 11q13 (Fig. 2) . SSCA analysis of the 9 coding exons of the MEN1 gene revealed no mutations in the 11 tumors analyzed. In 6 cases, a common polymorphism (GAC to GAT) involving codon 418 in exon 9 was detected. This polymorphism (Asp 418 Asp) was detected in both constitutional and tumor DNA and has been reported to occur in up to 44% of the population (6) .
LOH/AI in chromosome 2p16
LOH/AI on chromosome 2 was only detected in the carcinomas, with increasing frequency for markers within 2p16 (median, 72%; range, 54 -88%) compared to D2S319 in 2pter (8%) and D2S125 in 2qter (44%). Twelve of the 13 carcinomas showed LOH/AI for at least 1 of the 7 microsatellite markers from the 2p16 region typed (Fig. 3) . In 7 of these, all informative markers showed loss (tumors 1, 2, 3, 4, 6, 10, and 11). However, in the remaining 5 tumors, LOH/AI only occurred at some loci, whereas other loci showed retained heterozygosity (tumors 7, 8, 9, 12, and 13). Based on the results from tumors 9, 12, and 13, a single minimal region of overlapping deletions could be mapped between D2S391 and D2S288 (Fig. 3) . The interval between D2S391 and D2S288 defines a 1-centimorgan (cM) region that is separate from the location of the 6-cM CC region, as well as from the human MSH2, human MSH6, and POMC genes (Fig. 3) .
Discussion
In this study we have screened adrenocortical tumors for genetic alterations using microsatellite markers and SSCA analysis. The carcinomas showed a high percentage of LOH/AI at 11q13, but no mutations were detected in the MEN1 gene. LOH at 2p16 was found in almost all of the carcinomas, and a 1-cM target region outside the CC locus was delineated. The approach used in this study have identified some chromosome regions with frequent deletions, indicating that they may harbor TSGs important for the development and progression of this tumor form. However, this approach does not exclude that other chromosome regions may be of importance.
Adrenocortical tumors in MEN1 patients are always seen in conjunction with tumors in the endocrine pancreas (3, 4, 19) . LOH at 11q13 in adrenocortical lesions from MEN1 patients has to date only been reported in a rare case of an aldosterone-producing adenoma (20) and in one adrenocortical carcinoma (3). In our study of sporadic adrenocortical tumors, two benign tumors, both aldosteronomas, showed LOH at 11q13. This has previously been described in patients with familial hyperaldosteronism type II, in one sporadic aldosteronoma as well as in the MEN1 case mentioned above (20, 21) . The involvement of the MEN1 gene in the pathogenesis of sporadic adrenocortical tumors cannot be completely ruled out even though no mutations were found in this study. We employed the commonly used method of SSCA to screen for mutations. For the MEN1 gene this method has a detection rate of approximately 60 -80% in family studies and somewhat higher in studies of tumors with loss of one 11q13 allele. Clearly, one allele of the MEN1 gene is frequently lost, and other mechanisms than mutations within the coding part of the gene, such as splice mutations or hypermethylation of the promoter region, may be of importance. Furthermore, another gene in this chromosomal region may be involved.
It has not yet been established whether there is a progression of adrenocortical tumors from the benign to the malignant phenotype, or if malignant and benign tumors have different origins. It could be speculated, however, that adrenocortical cell proliferation may be initiated by a mitogen stimulus, which, in turn, facilitates for key genetic alterations to take place. Mutational events in genes that are important to maintain the stability of the genome may then lead to the multiple numerical and structural chromosomal aberrations seen in tumors larger than 4 -5 cm, as demonstrated in this study and previously (9) . Until mutations in genes have been identified that initiate the development and are involved in the malignant transformation of this tumor form, numerical changes in chromosomes and structural genetic changes at specific chromosome regions that occur in the carcinomas may work as a preoperative tumor marker for malignancy. Fluorescence in situ hybridization and/or PCR methods can be used on fine needle aspiration material obtained preoperatively.
As LOH/AI in 2p16 was found frequently in the carcinomas but not in the benign tumors, it indicates that the region is important in the malignant progression of adrenocortical tumors. Furthermore, the defined 1-cM interval between showing LOH/AI on chromosome 2. The location of the nine markers used on 2p16, the human MSH2 and -6 genes, and the CC region are marked. The tumor numbers refer to Table 2 , and the symbols are the same as those used in Fig. 2 . A minimal region of overlapping deletions in 2p16 was mapped to the 1-cM interval flanked by D2S391 and D2S288.
D2S391 and D2S288 separates from the location of the 6-cM CC region as well as from the human MSH2, huamn MSH6, and POMC genes. This would exclude the CC gene as the target for the 2p16 deletions found in this study. However, the CC locus can still be involved in adrenocortical tumors because of earlier published data on Carney tumors indicating that the CC gene may have a dominant, rather than a recessive, tumorigenic function (22) . The DNA repair genes located on 2p16 are other candidates, but are not likely to be involved because they are located outside the 1-cM interval, and no frequent finding of microsatellite instability was detected in this study.
In conclusion, gross genetic alterations seen in adrenocortical tumors are complex and an increased genetic instability is a feature of the malignant tumors. Further studies on the mechanisms that cause chromosomal instability in this tumor form may lead us to genes involved in the malignant transition. Isolation and characterization of the putative TSG in the 2p16 region may provide insights into such malignification of adrenocortical tumors. Furthermore, no mutations in the MEN1 gene was found in this study.
